MCID: PSY004
MIFTS: 72

Psychotic Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Psychotic Disorder

MalaCards integrated aliases for Psychotic Disorder:

Name: Psychotic Disorder 12 14
Psychotic Disorders 40 69
Mental or Behavioural Disorder 12
Mental Disorders 69
Psychotic 51

Classifications:

ICD10: 32


Summaries for Psychotic Disorder

MedlinePlus : 40 Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with psychoses lose touch with reality. Two of the main symptoms are delusions and hallucinations. Delusions are false beliefs, such as thinking that someone is plotting against you or that the TV is sending you secret messages. Hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there. Schizophrenia is one type of psychotic disorder. People with bipolar disorder may also have psychotic symptoms. Other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke. Treatment depends on the cause of the psychosis. It might involve drugs to control symptoms and talk therapy. Hospitalization is an option for serious cases where a person might be dangerous to himself or others.

MalaCards based summary : Psychotic Disorder, also known as psychotic disorders, is related to schizophreniform disorder and delusional disorder, and has symptoms including pseudobulbar behavioral symptoms, restlessness and catatonic reaction. An important gene associated with Psychotic Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Neuroscience and Circadian rythm related genes. The drugs Aripiprazole and Asenapine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality.

Related Diseases for Psychotic Disorder

Diseases related to Psychotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 schizophreniform disorder 33.2 COMT DRD2 NRG1 PRL
2 delusional disorder 32.3 DRD2 DRD3 DRD4
3 schizoaffective disorder 31.0 BDNF COMT DAOA DISC1 DRD2 DRD3
4 traumatic brain injury 30.7 BDNF COMT DRD2
5 brain injury 30.7 BDNF COMT DRD2
6 anxiety 30.4 BDNF COMT HTR2A SLC6A4
7 alexithymia 30.1 COMT DRD2 SLC6A4
8 asperger syndrome 30.1 DISC1 MAOB SHANK3 SLC6A4
9 cocaine dependence 30.1 DRD2 DRD3 SLC6A4
10 paranoid schizophrenia 30.0 BDNF COMT HTR2A SLC6A4
11 borderline personality disorder 30.0 BDNF COMT HTR2A SLC6A4
12 childhood-onset schizophrenia 30.0 COMT DAOA NRG1 PRL PRODH
13 temporal lobe epilepsy 29.8 BDNF RELN SLC1A1
14 post-traumatic stress disorder 29.8 BDNF COMT DRD2 HTR2A MAOB SLC6A4
15 schizophrenia 29.5 BDNF COMT DAO DAOA DISC1 DRD2
16 alcohol abuse 29.5 BDNF DRD2 DRD3 DRD4 PRL SLC6A4
17 personality disorder 29.3 BDNF COMT DRD2 DRD3 DRD4 HTR2A
18 bipolar i disorder 29.3 BDNF COMT DAO DTNBP1 HTR2A NRG1
19 alcohol dependence 29.3 BDNF COMT DRD2 DRD3 DRD4 HTR2A
20 early-onset schizophrenia 29.3 BDNF COMT DRD2 DRD3 DRD4 HTR2A
21 obsessive-compulsive disorder 29.3 BDNF COMT DRD2 DRD3 DRD4 HTR2A
22 attention deficit-hyperactivity disorder 29.1 BDNF COMT DRD2 DRD3 DRD4 HTR2A
23 mood disorder 29.0 BDNF COMT DAOA DISC1 DRD2 DRD4
24 autism spectrum disorder 28.7 BDNF COMT DISC1 DRD2 DRD3 DRD4
25 autism 28.7 BDNF COMT DISC1 DRD2 DRD3 DRD4
26 disease of mental health 28.1 BDNF COMT DISC1 DRD2 DRD3 DRD4
27 bipolar disorder 27.9 BDNF COMT DAO DAOA DISC1 DRD2
28 drug psychosis 11.0
29 mental retardation, x-linked, syndromic 13 10.8
30 schizophrenia 4 10.8
31 schizophrenia 2 10.8
32 schizophrenia 9 10.8
33 schizophrenia 15 10.8
34 chromosome 2p16.3 deletion syndrome 10.8
35 schizophrenia 18 10.8
36 schizophrenia 19 10.8
37 polysubstance abuse 10.6 COMT DRD2 DRD3
38 obsessive-compulsive personality disorder 10.5 DRD3 SLC6A4
39 hyperprolinemia 10.5 COMT PRODH
40 postpartum depression 10.5 BDNF COMT PRL SLC6A4
41 alzheimer disease 5 10.5 HTR2A SLC6A4
42 galactorrhea 10.5 DRD2 PRL
43 alcohol use disorder 10.5 DRD2 SLC6A4
44 social phobia 10.5 DRD2 PRL SLC6A4
45 opiate dependence 10.4 DRD2 DRD3 SLC6A4
46 atypical depressive disorder 10.4 MAOB SLC6A4
47 antisocial personality disorder 10.4 COMT DRD2 MAOB SLC6A4
48 cocaine abuse 10.4 DRD2 PRL SLC6A4
49 impulse control disorder 10.4 DRD2 DRD3 DRD4
50 eating disorder 10.4 BDNF COMT DRD2 SLC6A4

Graphical network of the top 20 diseases related to Psychotic Disorder:



Diseases related to Psychotic Disorder

Symptoms & Phenotypes for Psychotic Disorder

UMLS symptoms related to Psychotic Disorder:


pseudobulbar behavioral symptoms, restlessness, catatonic reaction, clouded consciousness, personality changes, mental and behavioral signs and symptoms, photophobia, sleep disturbances, symptoms, sluggishness, trembling inside, opiate withdrawal symptoms, feeling jittery, forgetful, numb mouth, agitation mental, depression aggravated, excitability, difficulty sleeping, restless sleep, hallucinations, sensory, depressed reaction, dejection emotional, floating feeling, feeling weightless, feeling strange, feeling detached, numbness localized, hallucinations, visual, hallucinations, auditory, psychiatric symptom, decrease in appetite, agitation, numbness, nervousness, lethargy, increased libido, alexithymia

GenomeRNAi Phenotypes related to Psychotic Disorder according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.36 PRODH
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.36 PRODH
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.36 PRODH
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.36 PRODH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.36 DRD3 PRODH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.36 DRD3 DRD4 PRODH
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.36 PRODH
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.36 PRODH

MGI Mouse Phenotypes related to Psychotic Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 SLC1A1 SLC6A4 DTNBP1 SHANK3 BDNF HTR2A
2 homeostasis/metabolism MP:0005376 10.16 SLC1A1 SLC6A4 SHANK3 DTNBP1 BDNF MAOB
3 nervous system MP:0003631 9.89 SLC1A1 SLC6A4 SHANK3 DTNBP1 BDNF MAOB
4 integument MP:0010771 9.85 SLC6A4 SHANK3 DTNBP1 BDNF MTHFR PRL
5 renal/urinary system MP:0005367 9.17 SLC1A1 RGS4 DTNBP1 MAOB COMT DRD2

Drugs & Therapeutics for Psychotic Disorder

Drugs for Psychotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1041)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
3
Chlorpromazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-53-3 2726
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
5
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
6
Sulpiride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 15676-16-1 5355
7 Benperidol Approved, Investigational Phase 4,Phase 2 2062-84-2
8 bromperidol Approved, Investigational Phase 4 10457-90-6
9
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 5786-21-0 2818
10
Fluphenazine Approved Phase 4,Phase 3,Phase 2 69-23-8 3372
11
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
12
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1 52-86-8 3559
13 Perazine Approved, Investigational Phase 4 84-97-9
14
Perphenazine Approved Phase 4,Phase 3,Phase 2,Phase 1 58-39-9 4748
15
Pimozide Approved Phase 4,Phase 3,Phase 2 2062-78-4 16362
16
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
17
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1 146939-27-7 60854
18
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
19
Zolpidem Approved Phase 4,Phase 3,Phase 2,Phase 1 82626-48-0 5732
20 Zotepine Approved, Investigational Phase 4 26615-21-4
21
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 298-46-4 2554
22
Coal tar Approved Phase 4,Phase 2 8007-45-2
23
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
24
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
25
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 20748-11-2, 113-45-1 4158
26
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
27
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
28
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 112111-43-0
29
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 68693-11-8 4236
30
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
31
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 29110-47-2 3519
32
Curcumin Approved, Investigational Phase 4,Phase 1,Phase 2 458-37-7 969516
33
Etomidate Approved Phase 4 33125-97-2 667484 36339
34
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 2078-54-8 4943
35
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
36
Reboxetine Approved, Investigational Phase 4,Phase 2,Phase 1 71620-89-8, 98769-81-4 65856 123628
37
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 10118-90-8 5281021
38
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-41-2 439260
39
Carbidopa Approved Phase 4,Phase 2,Phase 3,Phase 1 28860-95-9 38101 34359
40
Levodopa Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-92-7 6047
41
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
42
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
43
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 148553-50-8 5486971
44
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 53477758 439302
45
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
46
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
47
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
48
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
49
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 249296-44-4 5310966
50
Dronabinol Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 1972-08-3 16078 2978

Interventional clinical trials:

(show top 50) (show all 10000)

# Name Status NCT ID Phase Drugs
1 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
2 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
3 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4 Asenapine
4 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
5 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Unknown status NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
6 Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) Unknown status NCT01822418 Phase 4 agomelatine
7 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
8 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
9 A Pharmacokinetic Study of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
10 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
11 Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Unknown status NCT02307396 Phase 4 Olanzapine;Amisulpride;Risperidone;Haloperidol;Quetiapine;Perphenazine;Sulpiride;bromperidol;Zuclopenthixol;Thioridazine;Paliperidone;Ziprasidone;Benperidol;Fluspirilene;Pimozide;Perazine;Fluphenazine;Flupentixole;Sertindole
12 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
13 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
14 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
15 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
16 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
17 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
18 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
19 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
20 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
21 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
22 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
23 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
24 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
25 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
26 Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch Unknown status NCT02697045 Phase 4 Aripiprazole 400mg LAI
27 Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients Unknown status NCT02298985 Phase 4 Curcumin;placebo
28 Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia Unknown status NCT02282085 Phase 4 Aripiprazole Once-Monthly;Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
29 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
30 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4 Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole;Tandospirone
31 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4 Moxonidine;Placebo;Moxonidine;Placebo
32 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
33 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
34 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
35 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
36 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
37 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4 Risperidone;Paliperidone
38 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
39 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
40 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
41 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
42 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
43 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4 Risperidone, Haloperidol
44 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg)
45 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
46 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4 Intrinsa Transdermal testosterone patch
47 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
48 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
49 Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients Unknown status NCT01399450 Phase 4 paliperidone
50 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO

Search NIH Clinical Center for Psychotic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Psychotic Disorder

Anatomical Context for Psychotic Disorder

MalaCards organs/tissues related to Psychotic Disorder:

38
Brain, Testes, Eye, Heart, Cortex, Skin, Prefrontal Cortex

Publications for Psychotic Disorder

Articles related to Psychotic Disorder:

(show top 50) (show all 382)
# Title Authors Year
1
Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults. ( 29387876 )
2018
2
Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder. ( 29401155 )
2018
3
Mentalizing impairment as a mediator between reported childhood abuse and outcome in nonaffective psychotic disorder. ( 29145104 )
2018
4
Sibling bullying in middle childhood and psychotic disorder at 18 years: a prospective cohort study. ( 29429415 )
2018
5
Care Pathways Before First Diagnosis of a Psychotic Disorder in Adolescents and Young Adults. ( 29361848 )
2018
6
Evidence that reduced gray matter volume in psychotic disorder is associated with exposure to environmental risk factors. ( 29174764 )
2018
7
Abnormal frontoparietal synaptic gain mediating the P300 in patients with psychotic disorder and their unaffected relatives. ( 28345275 )
2017
8
GRIN3B missense mutation as an inherited risk factor for schizophrenia: whole-exome sequencing in a family with a familiar history of psychotic disorders. ( 28132660 )
2017
9
Diagnostic validity of ICD-10 acute and transient psychotic disorders and DSM-5 brief psychotic disorder. ( 28756108 )
2017
10
Clozapine Safety and Efficacy for Interictal Psychotic Disorder in Pharmacoresistant Epilepsy. ( 28632525 )
2017
11
Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case-Control Study of the ALSPAC Longitudinal Birth Cohort. ( 29036721 )
2017
12
The details of structural disconnectivity in psychotic disorder: A family-based study of non-FA diffusion weighted imaging measures. ( 28709907 )
2017
13
Anti-NMDA receptor encephalitis presenting as a primary psychotic disorder. ( 28738102 )
2017
14
Dopamine D2-receptor affinity of antipsychotics in relation to subjective well-being in patients with a psychotic disorder. ( 28542034 )
2017
15
Evidence That the Impact of Childhood Trauma on IQ Is Substantial in Controls, Moderate in Siblings, and Absent in Patients With Psychotic Disorder. ( 28177077 )
2017
16
Outcome of acute and transient psychotic disorder in an index episode: A study from a tertiary care centre in North India. ( 28262127 )
2017
17
The Relationship Between the Personality Inventory for the DSM-5 (PID-5) and the Psychotic Disorder in a Clinical Sample. ( 29214869 )
2017
18
Ethnic differences in physician follow-up after a first diagnosis of psychotic disorder. ( 28709775 )
2017
19
Cognitive changes in alcohol-induced psychotic disorder. ( 28446210 )
2017
20
Serum S100B: A proxy marker for grey and white matter status in the absence and presence of (increased risk of) psychotic disorder? ( 28358925 )
2017
21
Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder. ( 28648915 )
2017
22
Quantitative exploration of factors influencing psychotic disorder ailments in Nigeria. ( 28795095 )
2017
23
Intact striatal dopaminergic modulation of reward learning and daily-life reward-oriented behavior in first-degree relatives of individuals with psychotic disorder. ( 29233195 )
2017
24
Insight in body dysmorphic disorder (BDD) relative to obsessive-compulsive disorder (OCD) and psychotic disorders: Revisiting this issue in light of DSM-5. ( 28651226 )
2017
25
Exploring the use of Routine Outcome Monitoring in the treatment of patients with a psychotic disorder. ( 28314165 )
2017
26
Treatment of Alcohol-Induced Psychotic Disorder (Alcoholic Hallucinosis)-A Systematic Review. ( 29145545 )
2017
27
Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience. ( 28436345 )
2017
28
Clinical consequences of extensive routine laboratory investigations in patients with a recent onset psychotic disorder. ( 28162811 )
2017
29
Higher required dosage of antipsychotics to relieve the symptoms of first-onset Acute and Transient Psychotic Disorder (ATPD) predicted the subsequent diagnostic transition to schizophrenia: A longitudinal study. ( 28739289 )
2017
30
Antipsychotic treatment and the Rorschach Perceptual Thinking Index (PTI) in psychotic disorder patients: Effects of treatment. ( 28236781 )
2017
31
Outcome of first-episode acute and transient psychotic disorder in Hong Kong Chinese: a 20-year retrospective follow-up study. ( 27834101 )
2017
32
Auditory hallucinations, not necessarily a hallmark of psychotic disorder. ( 28826411 )
2017
33
Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. ( 28517032 )
2017
34
Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study. ( 28464965 )
2017
35
No Evidence of Association between Childhood Urban Environment and Cortical Thinning in Psychotic Disorder. ( 28045900 )
2017
36
Length during early childhood and later development of non-affective psychotic disorder. ( 29097001 )
2017
37
Is kidney transplantation safe after careful selection of the recipients with a history of psychotic disorder? ( 29024009 )
2017
38
Correction: No Evidence of Association between Childhood Urban Environment and Cortical Thinning in Psychotic Disorder. ( 28542397 )
2017
39
Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series. ( 29039260 )
2017
40
Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort. ( 28949339 )
2017
41
Does the Social Functioning Scale reflect real-life social functioning? An experience sampling study in patients with a non-affective psychotic disorder and healthy control individuals. ( 28534464 )
2017
42
Emergence of new-onset psychotic disorder following recovery from LGI1 antibody-associated limbic encephalitis. ( 28363946 )
2017
43
A case report of brief psychotic disorder with catalepsy associated with sequential life-threatening events in a patient with advanced cancer. ( 28413438 )
2017
44
Psychotic disorder associated with 22q11.2 duplication syndrome. ( 26763109 )
2016
45
Porencephalic cyst and late onset brief psychotic disorder. ( 27053544 )
2016
46
Influence of DAOA and RGS4 genes on the risk for psychotic disorders and their associated executive dysfunctions: A family-based study. ( 26803614 )
2016
47
Life-threatening ketoacidosis in a pregnant woman with psychotic disorder. ( 27512491 )
2016
48
Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? ( 27650124 )
2016
49
Early-Life Stress Affects Stress-Related Prefrontal Dopamine Activity in Healthy Adults, but Not in Individuals with Psychotic Disorder. ( 27007554 )
2016
50
Resilience in patients with psychotic disorder. ( 27110878 )
2016

Variations for Psychotic Disorder

Expression for Psychotic Disorder

Search GEO for disease gene expression data for Psychotic Disorder.

Pathways for Psychotic Disorder

Pathways related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1 12.09 COMT DTNBP1 RGS4 SHANK3 SLC1A1
3
Show member pathways
11.84 COMT DRD2 DRD3 DRD4 MAOB SHANK3
4
Show member pathways
11.74 BDNF DRD2 MAOB
5 11.71 HTR2A MAOB SLC6A4
6 11.64 DRD3 DRD4 HTR2A
7
Show member pathways
11.62 DRD2 DRD3 DRD4
8
Show member pathways
11.32 DRD2 DRD3 DRD4 HTR2A
9
Show member pathways
11.19 DAO MAOB PRODH
10
Show member pathways
10.58 COMT MAOB
11 10.51 COMT MAOB

GO Terms for Psychotic Disorder

Cellular components related to Psychotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 DRD2 DRD3 DRD4 HTR2A NRG1 SLC1A1
2 postsynaptic membrane GO:0045211 9.67 COMT DISC1 DTNBP1 SHANK3
3 postsynaptic density GO:0014069 9.62 DISC1 DRD2 DTNBP1 SHANK3
4 dendrite GO:0030425 9.55 COMT DRD2 HTR2A NRG1 RELN
5 axon GO:0030424 9.35 COMT DRD2 DTNBP1 HTR2A NRG1
6 dendritic spine GO:0043197 8.92 COMT DRD2 DTNBP1 SHANK3
7 plasma membrane GO:0005886 10.07 COMT DISC1 DRD2 DRD3 DRD4 DTNBP1

Biological processes related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.87 DRD2 DRD3 MAOB
2 response to drug GO:0042493 9.87 COMT DRD2 DRD3 HTR2A MAOB MTHFR
3 response to toxic substance GO:0009636 9.86 DRD2 MAOB SLC6A4
4 cellular calcium ion homeostasis GO:0006874 9.84 DRD3 DRD4 HTR2A
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 HTR2A NRG1 RELN
6 locomotory behavior GO:0007626 9.83 DRD2 DRD3 NRG1 SHANK3
7 memory GO:0007613 9.81 HTR2A SHANK3 SLC6A4
8 negative regulation of adenylate cyclase activity GO:0007194 9.77 DRD2 DRD3 DRD4
9 learning GO:0007612 9.76 COMT DRD3 RELN SHANK3
10 response to amphetamine GO:0001975 9.73 DRD2 DRD3 DRD4
11 synapse assembly GO:0007416 9.73 BDNF DRD2 NRG1 SHANK3
12 arachidonic acid secretion GO:0050482 9.71 DRD2 DRD3 DRD4
13 synaptic transmission, dopaminergic GO:0001963 9.69 DRD2 DRD3
14 brain morphogenesis GO:0048854 9.69 SHANK3 SLC6A4
15 dopamine receptor signaling pathway GO:0007212 9.69 DRD2 DRD3 DRD4
16 glial cell differentiation GO:0010001 9.68 NRG1 RELN
17 startle response GO:0001964 9.68 DRD2 NRG1
18 positive regulation of kinase activity GO:0033674 9.68 DRD4 HTR2A
19 behavioral response to ethanol GO:0048149 9.67 DRD2 DRD4
20 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.67 DRD2 HTR2A
21 negative regulation of protein secretion GO:0050709 9.67 DRD2 DRD3 DRD4
22 social behavior GO:0035176 9.67 DRD3 DRD4 SHANK3 SLC6A4
23 negative regulation of voltage-gated calcium channel activity GO:1901386 9.66 DRD2 DRD4
24 prepulse inhibition GO:0060134 9.66 DRD2 DRD3
25 positive regulation of renal sodium excretion GO:0035815 9.65 DRD2 DRD3
26 G-protein coupled receptor internalization GO:0002031 9.65 DRD2 DRD3
27 positive regulation of long-term synaptic potentiation GO:1900273 9.65 DRD2 RELN SHANK3
28 neurotransmitter catabolic process GO:0042135 9.64 COMT MAOB
29 regulation of behavior GO:0050795 9.64 HTR2A RELN
30 dopamine catabolic process GO:0042420 9.63 COMT MAOB
31 regulation of cAMP metabolic process GO:0030814 9.62 DRD2 DRD3
32 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.62 DRD2 DRD3
33 positive regulation of AMPA receptor activity GO:2000969 9.61 RELN SHANK3
34 NMDA glutamate receptor clustering GO:0097114 9.61 RELN SHANK3
35 proline catabolic process GO:0006562 9.6 DAO PRODH
36 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.58 DRD2 DRD4
37 negative regulation of dopamine receptor signaling pathway GO:0060160 9.58 DRD2 DRD3
38 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD3 DRD4
39 acid secretion GO:0046717 9.57 DRD2 DRD3
40 regulation of dopamine secretion GO:0014059 9.56 DRD2 DRD3 DTNBP1 HTR2A
41 regulation of locomotion involved in locomotory behavior GO:0090325 9.55 DRD2 DRD3
42 behavioral response to cocaine GO:0048148 9.46 DRD2 DRD3 DRD4 HTR2A
43 response to histamine GO:0034776 9.13 DRD2 DRD3 DRD4
44 dopamine metabolic process GO:0042417 8.92 COMT DRD2 DRD3 DRD4

Molecular functions related to Psychotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.56 DRD2 DRD3 DRD4 HTR2A
2 dopamine binding GO:0035240 9.33 DRD2 DRD3 DRD4
3 G-protein alpha-subunit binding GO:0001965 9.32 HTR2A RGS4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD2 DRD3 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD2 DRD3 DRD4

Sources for Psychotic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....